View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, March 15 (HealthDay News) -- Warfarin-treated patients may be at a higher risk for symptomatic intracerebral hemorrhage after treatment for acute ischemic stroke (AIS) with intravenous tissue plasminogen activator (IV tPA) than their counterparts not being prescribed warfarin, according to a study published online March 8 in the Archives of Neurology.
Shyam Prabhakaran, M.D., of the Rush University Medical Center in Chicago, and colleagues conducted a study of 107 patients (mean age, 69.2 years). The participants had a median National Institutes of Health Stroke Scale score of 14, a median international normalized ratio of 1.04, and a median onset-to-treatment time of 140 minutes. In all, 12.1 percent were taking warfarin at baseline.
The researchers found that the overall symptomatic intracerebral hemorrhage rate was 6.5 percent, but this was almost 10 times higher among those on warfarin at baseline compared with those not taking the drug. Even after adjusting for potential confounding factors such as age, atrial fibrillation and stroke scale score, the association remained strong.
"Our preliminary data raise potential safety concerns regarding the currently accepted guideline of IV tPA use in warfarin-treated patients presenting with AIS in whom the baseline international normalized ratio is less than 1.7," the authors write. "Larger prospective studies to confirm our preliminary findings are warranted."
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top